Laurel Habel to Chemotherapy, Adjuvant
This is a "connection" page, showing publications Laurel Habel has written about Chemotherapy, Adjuvant.
Connection Strength
0.425
-
Adjuvant endocrine therapy for breast cancer patients: impact of a health system outreach program to improve adherence. Breast Cancer Res Treat. 2020 Feb; 180(1):219-226.
Score: 0.178
-
Declining recurrence among ductal carcinoma in situ patients treated with breast-conserving surgery in the community setting. Breast Cancer Res. 2009; 11(6):R85.
Score: 0.088
-
Racial/ethnic differences in use and duration of adjuvant hormonal therapy for breast cancer in the women's health initiative. Cancer Epidemiol Biomarkers Prev. 2013 Mar; 22(3):365-73.
Score: 0.027
-
Patterns and predictors of breast cancer chemotherapy use in Kaiser Permanente Northern California, 2004-2007. Breast Cancer Res Treat. 2013 Jan; 137(1):247-60.
Score: 0.027
-
Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst. 2012 Sep 05; 104(17):1293-305.
Score: 0.027
-
Racial and ethnic differences in adjuvant hormonal therapy use. J Womens Health (Larchmt). 2012 Sep; 21(9):950-8.
Score: 0.026
-
Validity of eight integrated healthcare delivery organizations' administrative clinical data to capture breast cancer chemotherapy exposure. Cancer Epidemiol Biomarkers Prev. 2012 Apr; 21(4):673-80.
Score: 0.026
-
Racial/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor-positive breast cancer. Breast Cancer Res Treat. 2012 Jan; 131(2):607-17.
Score: 0.025